About Viking Therapeutics Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://vikingtherapeutics.com/
Frequently Asked Questions
What is the 52-week range for VKTX?
The 52-week high is $43.15 and the 52-week low is $25.77.
What is the P/E ratio for VKTX?
The P/E ratio data is currently unavailable.
What is the dividend yield for VKTX?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -94.56%.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 6.22.
Analyst Recommendation Trends
Wall Street analyst consensus for VKTX over the last few months:
Latest VKTX News
Does Viking Therapeutics (VKTX) Pairing VK2735 Data With Fresh Capital Signal A Sharpened Obesity Strategy?
Viking Therapeutics recently completed a US$225,000,000 convertible bond offering and a US$275,000,005 follow-on equity raise, soon after reporting past positive top-line results from its VK2735 obesity maintenance trial showing strong weight loss retention with less frequent dosing and a placebo-like safety profile. The company’s ability to pair compelling VK2735 maintenance data with substantial new financing highlights how clinical progress is being matched by balance sheet reinforcement...
Should You Buy Viking Therapeutics Stock While It Trades Below Its $35 Offering Price?
The weight loss drug company continues to make progress, but its share price is bouncing around with events.
LLY Highlights New Efficacy Data From Foundayo and EloraTZP Studies
Eli Lilly's new data show Foundayo's cardiovascular safety and metabolic benefits, while EloraTZP delivers greater weight loss and A1C reduction in a mid-stage study.
Prediction: This Stock Could Double Over the Next 5 Years
The obesity drug market is so large that only a small market share could lead to substantive price appreciation for the stock.
Viking Therapeutics, Inc. (VKTX) Stock Declines While Market Improves: Some Information for Investors
Viking Therapeutics, Inc. (VKTX) closed the most recent trading day at $30.51, moving 6.41% from the previous trading session.
Novo Is Open to Acquisitions. Here Are 2 Companies That Would Be Great Candidates to Buy
Could this be what Novo needs to turn things around?
Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock.
There could be more catalysts for the biotech over the next 18 months.
Viking Therapeutics, Inc. (VKTX) Rises As Market Takes a Dip: Key Facts
Viking Therapeutics, Inc. (VKTX) concluded the recent trading session at $32.74, signifying a +2.92% move from its prior day's close.
3 Emerging Biotech Stocks With Significant Upside Potential
Delcath Systems, Viking Therapeutics and AxoGen show growth potential backed by analyst Moderate Buy ratings and strong institutional ownership, despite risks like dilution and patent cliffs.
Can Novo's Licensing Strategy Build Its Next Wave of Oral Medicines?
NVO's latest Hengrui deal adds a phase I-ready, once-weekly oral GLP-1/GIP candidate, building on deals for oral drug-delivery tech and small-molecule approaches.
Eli Lilly Stock Barely Moved Following Viking Therapeutics' Impressive Clinical Results. Here's Why.
Both stocks may be worth considering for those looking to capitalize on the anti-obesity market.
3 Non-AI Growth Stocks That Have Massive Upside
Investors looking for some compelling growth opportunities outside of tech may want to consider these stocks.
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders will
Dow, S&P 500, Nasdaq Futures Fall Amid Rising Bond Yields, AI Concerns: KOD, SMMT, CLF, VKTX Stocks In Focus
U.S. stock markets were rattled by rising Treasury yields even as oil prices surged and additional concerns about the artificial intelligence sector weighed on investor sentiment.
VKTX Stock Logs 3-Day Losing Streak As $548M Raise Closes — Retail Calls Dip An ‘Easy Buy’ Amid Buyout Talks
Underwriters exercised their options in full, lifting the financing above Viking’s initial $400 million proposal.
Viking Therapeutics Announces Closing of Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares of Common Stock and Convertible Senior Notes
Viking Therapeutics, Inc. (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the closing of its concurrent upsized public offerings of 9,035,714 shares of common stock, at a public offering price of $35.00 per share, and $258.75 million aggregate principal amount of 2.00% convertible senior notes due 2032 (the "notes"), which included the full exercise by the underwriters of the common st
Could This Mid-Cap GLP-1 Stock Be a Better Buy Than Eli Lilly?
Shares of Viking Therapeutics took off recently after the company released some promising data about its GLP-1 drug.
Wall Street Analysts Think Viking Therapeutics (VKTX) Is a Good Investment: Is It?
Based on the average brokerage recommendation (ABR), Viking Therapeutics (VKTX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Viking Therapeutics Adds Weight Loss Maintenance As Potential New Growth Driver
Viking Therapeutics' VK2735 obesity trial shows strong weight loss and better tolerability. Read the latest analysis on the VKTX stock here.
Viking Therapeutics (VKTX) Delivers Great VK2735 Results: Here's a Word of Caution
The company recently delivered some exciting trial data, but it also needs to deliver in the second part of the trial.
3 Numbers From Viking Therapeutics' Weight-Loss Drug Trial That Have Wall Street Buzzing
The company continues to make good progress with its key obesity treatment drug, VK2735.
MarketBeat Week in Review – 09/21 - 09/25
A weekly roundup of MarketBeat analysis on volatile markets, oil, bond rates, AI stocks, dividend picks, and earnings outlooks, covering companies from NVIDIA to Tesla and Qualcomm.
Benzinga Bulls and Bears: Costco, KB Home, McDonald’s
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.
Is Viking Therapeutics (VKTX) Getting Too Rich After VK2735 Data?
Viking Therapeutics has ridden a powerful share price run and a wave of enthusiasm around its weight loss pipeline. This now puts a spotlight on a quieter question. At today’s level, the issue is whether the stock price lines up with the biopharma group’s book value when set against the industry average. Over the past 5 years, Viking Therapeutics has delivered a very large share price gain. This raises the stakes for whether current investors are paying a level that its balance sheet can...
Stock Market Split As Nasdaq Hits High, Dow Jones Slides Amid Surging Treasury Yields: Weekly Review
The Nasdaq hit a new high this week, but the Dow Jones set fresh three-month lows as Treasury yields skyrocketed.
Viking Therapeutics Soared After Its Latest GLP-1 Data. Is It Too Late to Buy?
The biotech player could eventually rival big pharma companies.
Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Viking Therapeutics, Inc. (VKTX) closed the most recent trading day at $36.75, moving 11.76% from the previous trading session.
One investor reportedly took a third of Viking’s share sale
Investing.com -- Viking Therapeutics Inc. completed a $500 million capital raise through a two-part offering, with one investor acquiring approximately one-third of the shares in the upsized equity portion, Bloomberg reported Thursday.
Here's Why Viking Therapeutics Shares Slumped Today
It's been an eventful week for the weight-loss drug company, which continues to impress with its clinical data, and today's move isn't much to worry about.
Viking Therapeutics Sinks 12% on “Upsized” $500 Million Raise
Viking Therapeutics (VKTX) shares are down about 12% this morning after the company priced a $500 million raise. Two days ago, when the stock soared on its maintenance study results, I wrote that “if management needs to dilute shareholders with a follow-on equity offering, I expect plenty of takers.
Viking Therapeutics Sinks 15% After Pricing Upsized $500M Offering; Jaguar Health Tumbles 25%
Two biotech stocks are getting crushed while the sector benchmark climbs, and the reasons behind each selloff could not be more different. Understanding what separates a deliberate corporate move from pure micro-cap chaos is the key to reading both situations correctly.
S&P 500 Erases Losses as US, Iran Reportedly Discuss Hormuz Deal: Stock Market Today
Stocks pared a sharp morning selloff after sources said US and Iranian negotiators are discussing a phased deal to reopen the Strait of Hormuz.
VKTX Stock Heads Toward Worst Day In Over A Year Just Days After Promising Weight Loss Drug Data — Here’s What’s Driving The Selloff
Viking Therapeutics priced an upsized financing deal at a 16% discount from the stock’s closing price on Wednesday.
Crude Oil Rises Over 4%; Darden Earnings Miss Views
U.S. stocks fell Thursday: Dow -0.7%, S&P 500 -0.46%, Nasdaq -0.7%. Oil jumped 4.4%; Darden missed estimates, while APUS surged 163%.
Why Is Viking Therapeutics Stock Trading Down Thursday?
A Viking Therapeutics announcement about an equity and debt offering fuels a reaction in the market.
Viking Therapeutics Prices Upsized $500 Million Offering of Common Stock and Convertible Senior Notes
Viking Therapeutics, Inc. (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the pricing of its concurrent public offerings of 7,857,143 shares of common stock, at a public offering price of $35.00 per share, and $225.0 million aggregate principal amount of 2.00% convertible senior notes due 2032 (the "notes"). The offering size of each of the common stock offering and note offering was i
Novo Nordisk: Capital Markets Day Reveals Its Next Growth Engine
Novo Nordisk A/Sâs 2030 pipeline targets, Wegovy pill growth and Q2 sales show major upside. Click for this NVO stock update.
Nasdaq, S&P 500 Futures Slide As Treasury Yields, Trump-Xi Summit Keep Traders On Edge: META, GOOGL, SPCX, VKTX, SNAP, MCD, BB Stocks In Focus
Retail sentiment on Stocktwits for SPY and QQQ has improved to ‘bullish’.
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Profusa (NASDAQ:PFSA) stock increased by 112.5% to $4.36 during Thursday's pre-market session. The company's market cap stands at $1.2 million. GlucoTrack (NASDAQ:GCTK) stock rose 96.55% to $3.99. The
Stitch Fix Posts Mixed Q4 Results, Joins Viking Therapeutics And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
U.S. futures fell as Stitch Fix plunged 18% on weak FY27 guidance; MGM, Viking Therapeutics and other stocks also declined premarket.
Viking Therapeutics Prices Concurrent Public Offerings Of 7,857,143 Shares At $35/Shr And $225M Aggregate Principal Amount Of 2.00% Convertible Senior Notes Due 2032
Viking Therapeutics, Inc. (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the pricing of its concurrent
Why GlucoTrack Shares Are Trading Higher By Around 118%; Here Are 20 Stocks Moving Premarket
GlucoTrack surged 117.7% premarket after Lokahi Therapeutics signed its first external partnership; other stocks saw notable gains and losses.
VKTX Stock Eyes Blockbuster Week Despite Share Offering — Retail Traders See A Stronger Hand In Buyout Talks
Retail traders floated Novo Nordisk, AbbVie and Eli Lilly as possible buyers, while others saw the offering as a sign Viking may go it alone.
VKTX Stock Slides After-Hours On $400M Stock-And-Notes Raise After Tuesday’s Rally
The San Diego biotech said it intends to offer $200 million of common stock and $200 million of convertible senior notes due 2032, subject to market conditions.
Viking Therapeutics, Inc. (VKTX) Gains As Market Dips: What You Should Know
The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $41.65, representing a +1.96% change from its previous close.
Viking Therapeutics Announces Proposed Offerings of Common Stock and Convertible Senior Notes
Viking Therapeutics, Inc. (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its intention to offer, subject to market and other conditions, $200.0 million of common stock and $200.0 million aggregate principal amount of convertible senior notes due 2032 (the "notes") in separate public offerings registered under the Securities Act of 1933, as amended. Viking also expects to grant the und
Viking's Obesity Edge May Be Staying Power, Not Weight Loss
Viking Therapeutics shares jumped 36% after VK2735 maintenance data showed patients kept most weight loss on less frequent dosing, though Phase 3 results and commercial funding remain unresolved.
Viking Therapeutics Stock Drops In After Hours on Proposed Public Offerings
Viking Therapeutics shares are moving lower in extended trading Wednesday after the company announced a pair of proposed public offerings.
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers GlucoTrack (NASDAQ:GCTK) stock moved upwards by 90.6% to $3.87 during Wednesday's after-market session. The market value of their outstanding shares is at $1.7 million. Greenland Mines (NASDAQ:GRML) shares
QUICK SPARK: Viking Therapeutics Stock Gains 40% in 2 Days
Viking Therapeutics stock jumps 40% after VK2735 shows sustained weight loss with less frequent dosing.
Viking Therapeutics Announces $200M Common Stock And $200M Convertible Senior Notes Due 2032; Proceeds To Fund VK2735, VK3019 Clinical Development And General Corporate Purposes
Viking Therapeutics, Inc. (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its intention to offer, subject to
Two Biotechs Get Beaten Down: Jaguar Health Collapses 59%, Viking Therapeutics Sinks 4%
Jaguar Health and Viking Therapeutics are both sinking Wednesday morning, but the forces behind each drop point in completely different directions, and the broader biotech sector is barely flinching.
Can Novo's Rare Disease Pipeline Add a New Growth Pillar Beyond GLP-1?
NVO's rare disease pipeline gains momentum as Frehemgo and Sogroya receive positive CHMP opinions for EU approval, opening new growth opportunities beyond GLP-1.
VKTX Stock Rises on Encouraging Weight-Loss Maintenance Results
Viking Therapeutics' shares jump 36% as VK2735 maintenance data show most weight loss is preserved with less-frequent dosing.
Viking Therapeutics: 'Strong Buy' On Injectable VK2735 Maintenance Data And Treatment Optionality
Viking Therapeutics maintains a 'Strong Buy' rating, driven by positive phase 2 and maintenance data for its dual GLP-1/GIP agonist VK2735. Click for more.
Viking Therapeutics Stock Surges 36% Following Weight Loss Drug Study Results
Key Stats for Viking Therapeutics StockPrice change for Viking Therapeutics stock Today: 36%$VKTX Stock Price as of Sep. 22: $4152-Week High: $43$VKTX Stock Price Target: $92What Happened?Viking Therapeutics (VKTX) stock jumped more than 35% on Tuesday after the company released new data on its obesity drug, VK2735.
6 ‘Moonshot’ Biotech Stocks That Offer Big Risks, Bigger Rewards
Morgan Stanley highlights high-risk, high-reward biotech stocks poised for massive upside following key upcoming clinical readouts.
Truist Securities Maintains Buy on Viking Therapeutics, Raises Price Target to $87
Truist Securities analyst Joon Lee maintains Viking Therapeutics (NASDAQ:VKTX) with a Buy and raises the price target from $83 to $87.
The Stock Market Is Sleeping on the Next Big AI Catalyst
Meta’s annual conference kicks off today, and the latest on Anthropic's IPO, but this is the next big AI catalyst.
MARKETS LIVE: Futures slip ahead of Meta address
Dow Jones futures: 52,160.00, down 119.00 points. S&P 500 futures: 7,823.50, down 8.25 points. Nasdaq 100 futures: 30,933.00, down 95.50 points. FTSE 100: 10,693.46, down 14.87 points. 8.00 ET: Wall Street preview Wall Street was set for a softer open. Quotes showed...
Viking Therapeutics (VKTX) Reports VK2735 Trial Data, Is The Stock Fully Priced?
Viking Therapeutics (VKTX) is back in focus after the company reported positive top-line data from its VK2735-102 maintenance trial and scheduled a special call to walk through the obesity drug findings with investors. The special call and VK2735 update arrive after a sharp move in Viking Therapeutics’ shares, with a 1-day share price return of 35.67% and a 7-day share price return of 36.39%, while the 1-year total shareholder return of 63.60% and very large 5-year total shareholder return...
Why Viking Therapeutics Stock Skyrocketed on Tuesday
The biotech's obesity drug candidate could make it easier for people who have recently lost weight to keep it off.
Viking Therapeutics Soars as Weight-Loss Drug Trial Addresses GLP-1 Weakness
Research has shown the adherence rates of patients on GLP-1 therapies can fall as low as 27% after one year.
Obesity titan could shake up Lilly and Novo after astonishing trial
The San Diego company’s flexible dosing results could carve out real market share in the obesity drug race.
VKTX Stock On Track To Beat LLY, NVO This Month After Obesity Drug Data — Can Viking Win Over Wegovy And Zepbound Users?
Obesity specialist Lou Aronne said switching from a GLP-1 drug to a dual GLP-1/GIP drug could mean greater weight loss.
Dow, S&P 500, Nasdaq Futures Climb Amid Iran Diplomacy Hopes, AI Rally: IONQ, VKTX, INFQ, BB Stocks In Focus
President Donald Trump confirmed that U.S. and Iranian officials met on the sidelines of the United Nations General Assembly on Tuesday.
Viking Therapeutics, Inc. (VKTX) Discusses Top Line Data from VK2735 Maintenance Study in Obesity and Type 2 Diabetes - Slideshow
2026-09-22. The following slide deck was published by Viking Therapeutics, Inc.
Viking Therapeutics (VKTX) Rockets 35.7% After Weight Loss Drug Trial — What’s The Selling Point?
Viking Therapeutics Inc. (NASDAQ:VKTX) soared by a whopping 35.67 percent on Tuesday to close at $40.85 apiece—just $2 shy of its 52-week high—after reporting stellar results from its weight loss drug candidate, VK2735. After 21 weeks of clinical trial, the company said that enrolled patients who took VK2735 successfully lost 16 to 19 percent of […]
Lilly Rises Higher as Viking Preserves Up to 90% Monthly
Less-frequent injections could challenge chronic-treatment economics long before Viking reaches the market.
Nasdaq Jumps To Close At Record As Chipmakers Climb, Oil Prices Cool — AAPL, META, SPCX, MSFT, VKTX In Focus
Wall Street is gearing up for this week’s summit between Donald Trump and Chinese President Xi Jinping.
Jaguar Health, IONQ, Viking Therapeutics, Xanadu Quantum and Grab Holdings: Why These 5 Stocks Are on Investors' Radars Today
JAGX, IONQ, VKTX, XNDU, GRAB were among the stocks seen trending on Tuesday, Sept. 22, 2026.
Sandisk, Lennar, Viking Therapeutics, Shopify, GameStop, and More Stocks That Explain Today’s Market
Sandisk rises. Rosenblatt initiates coverage of the stock with a Buy rating and a price target of $2,400.
VKTX Stock Jumps 36% As Oppenheimer Hikes Target, Peers Call Data A Win
The San Diego company is trying to carve out a place beside Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy with a dual GLP-1/GIP drug that can be given as a shot or, later, a pill.
Viking Therapeutics Skyrockets On Obesity Drug Data. Eli Lilly, Novo Fall.
Viking Therapeutics and Roche both reported positive obesity drug data early Tuesday. Viking stock surged. Eli Lilly and Novo fell.
Beyond Eli Lilly and Novo Nordisk: Rising Obesity Drug Stocks to Watch
Viking Therapeutics and Roche are developing drugs for obesity and diabetes to challenge Eli Lilly and Novo Nordisk’s market duopoly.
Sector Update: Healthcare Stocks Rise Late Afternoon
Healthcare stocks rose late Tuesday afternoon, with the NYSE Healthcare Index adding 0.5% and the St
Viking Therapeutics Soars 36% on Clinical Trial Results: “An Important Step”
Shares of Viking Therapeutics (VKTX) are soaring 36% today on impressive new results in an early-stage maintenance study of VK2735, its dual GLP-1 and GIP agonist. What exactly happenedViking’s maintenance study read out today, and the headline numbers are eye-popping: 22% placebo-adjusted weight loss at week 33 (weekly dosing)Up to 97%(!) of weight loss from the weekly phase retained after moving to biweekly dosing for three monthsUp to 90% of weight loss retained after moving to monthly dosing
VKTX Stock Soars as Viking Therapeutics Announces Positive GLP-1 Trial Results
Viking Therapeutics shares rally on promising Phase 2 data for its candidate weight-loss treatment. Here’s why caution is still warranted in buying VKTX stock today.
Which stocks are experiencing notable movement on Tuesday?
Wondering how the US markets performed one hour before the close of the markets on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis.
Viking Soars Alone as Obesity Complex Shrugs at Strong GLP-1 Results
Viking Therapeutics surged more than 26% on fresh GLP-1 maintenance data while every major obesity peer from Eli Lilly to Novo Nordisk barely registered a pulse, raising a pointed question about whether this catalyst belongs to Viking alone or signals something bigger.
Viking Therapeutics VK2735 weight loss maintenance trial results
Patients who switched from weekly to monthly injections of VK2735 retained most of their weight loss, with side effects similar to placebo
What's going on in today's session
Wondering how the US markets performed in the middle of the day on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis.
Viking shares surge on updated obesity drug data
Trial participants mostly kept their weight down after switching from a weekly shot to less frequent dosing — findings that could strengthen Viking’s “competitive positioning,” one analyst wrote.
Top Midday Stories: Goldman Reportedly in Talks to Acquire $37 Billion Credit Firm Palmer Square; Viking Obesity Drug Candidate Showed 'Superior' Results in Study
The Nasdaq Composite was up, the Dow Jones Industrial Average was down, and the S&P 500 Index was ro
Viking Therapeutics, Inc. (VKTX) Discusses Top Line Data from VK2735 Maintenance Study in Obesity and Type 2 Diabetes Transcript
Viking Therapeutics, Inc. (VKTX) Discusses Top Line Data from VK2735 Maintenance Study in Obesity and Type 2 Diabetes September 22, 2026 8:00 AM EDTCompany...
Alibaba Higher on Chip News; On Holdings Football Move | Stock Movers
On this episode of Stock Movers: - Alibaba (BABA) shares are higher this morning after the company rolled out what it calls China's most powerful AI chip and announced plans to expand data center capacity in the coming years. - ON Holdings (ONON) is getting a boost as it expects sales growth in the high teens over the next few years as it moves into sports including golf and football. - Viking Therapeutics (VKTX) shares surged after the biotech released data from its VK2735-102 maintenance study showing VK2735, its experimental obesity drug, maintained up to 97% of weight loss versus 61% for placebo when subjects switched to every-other-week dosing. Leerink analysts said the "stellar" data strengthens the drug's competitive profile.
Viking Therapeutics Stock Soars After Obesity Drug Delivers 22% Weight Loss
Viking Therapeutics Surges on Breakthrough Obesity Drug Results
Viking Therapeutics shares surge over 27% on weight loss drug maintenance data
Viking Therapeutics (NASDAQ:VKTX), the clinical-stage biopharmaceutical company, surged over 27% in Tuesday morning trade after reporting trial data showing its obesity drug VK2735 maintained most patients’ initial weight loss with less frequent dosing. The drug, a dual agonist targeting the...
Gapping stocks in Tuesday's session
The market is buzzing with gapping stocks on Tuesday. Let's uncover which stocks are experiencing notable gaps during today's session.
Crude Oil Down Over 1%; Thor Industries Shares Gain After Q4 Results
U.S. stocks were mixed: Nasdaq and S&P 500 rose while the Dow fell; communication services gained, financials dropped, and Thor Industries climbed 5%.
Nasdaq 100 Flirts with Records, Oil Sinks for Fifth Day: Stock Market Today
Nasdaq 100 printed an intraday record on AI enthusiasm while financials slid nearly 2% and crude fell for a fifth straight session.
Viking Therapeutics stock surges on promising weight-loss data: A closer look
Viking Therapeutics (VKTX) stock is surging after the company released trial data showing that its obesity drug resulted in 22% weight loss. Yahoo Finance Breaking Business News Reporter Jake Conley, Yahoo Finance Senior Autos Reporter Pras Subramanian, and Yahoo Finance's Julie Hyman discuss the details in the video above.
Viking Therapeutics’ VK2735 Shows Strong Weight-Loss Retention With Monthly Dosing
Viking Therapeutics (NASDAQ:VKTX) reported top-line results from a maintenance dosing study of VK2735, its dual GLP-1/GIP receptor agonist candidate for obesity, showing that participants retained much of their initial weight loss after transitioning from weekly treatment to every-other-week or mont
Viking Therapeutics Shares Surge 27% Following VK2735 Weight-Loss Study Results
Viking Therapeutics (NASDAQ:VKTX) shares rose 27% on Tuesday after the company reported positive topline results from a study evaluating maintenance dosing schedules for its investigational obesity treatment VK2735. The San Diego-based biopharmaceutical company said the findings demonstrated the potential for patients to maintain much of their initial weight loss with less frequent injections following a period of weekly treatment.
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Jaguar Health (NASDAQ:JAGX) stock increased by 304.5% to $10.8 during Tuesday's regular session. The company's market cap stands at $1.1 million. Greenland Mines (NASDAQ:GRML) shares moved upwards by
Tuesday's pre-market session: top gainers and losers
The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Wall Street Lunch: Meta's Muse Teams With Shopify After Amazon Ban
Shopify welcomes Meta's AI shopping agent after Amazon blocks it. Viking soars after its obesity drug delivers 22% weight loss. DoorDash admits it screwed up after drivers lost tips.
On Holding, Viking Therapeutics, Shopify And Other Big Stocks Moving Higher On Tuesday
U.S. stocks rose, led by On Holding's 13% surge after strong guidance and a $1B buyback; Viking Therapeutics and others also gained.
Weight Loss Drug: Viking Therapeutics Says Lead Obesity Drug Shows Weight Retention with Less Frequent Dosing
Viking Therapeutics reports positive VK2735 study results showing effective weight maintenance with monthly and biweekly dosing regimens.
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Decoy Therapeutics (NASDAQ:DCOY) shares rose 84.0% to $4.71 during Tuesday's pre-market session. The company's market cap stands at $1.6 million. Greenland Mines (NASDAQ:GRML) shares rose 39.21% to
Viking Therapeutics: The Market Might Shrug Off The Maintenance Data
Viking Therapeutics is advancing VK2735 for obesity and diabetes, with key maintenance study data expected in Q3 '26. Learn why VKTX stock is a hold.
Market-Moving News for September 22nd
VICR: 13% | Vicor shares are trading higher after the company raised its Q3 revenue guidance. VKTX: 38% | Viking Therapeutics Announces Top-line Results From Maintenance Study Of VK2735, A Dual Agonist Of GLP-1 And
Viking Therapeutics Announces Top-line Results From Maintenance Study Of VK2735, A Dual Agonist Of GLP-1 And Glucose-Dependent Insulinotropic Polypeptide Receptors; 22% Placebo-Adjusted Weight Loss Reported At Week 33 Following Weekly Dosing Of VK2735At 17.5 MG; No Plateau Observed
Results Demonstrate Viability of Monthly and Every Other Week Dosing Regimens for Maintaining Weight Loss; Increasing Options for Adherence to TreatmentUp to 97% of Weight Loss Maintained Following Transition to Every
Novo Nordisk Falls 7% as Post-Wegovy Growth Plan Fails to Ease Competition Fears; Eli Lilly Slips, Viking Therapeutics Edges Higher
Novo Nordisk (NYSE:NVO) laid out its long-term growth strategy at a capital markets day in London Monday morning, and the plan didn’t calm investor worries about the company’s ability to defend the weight-loss market it helped build. That response is concentrated in the stock itself rather than in the broader group, which suggests a company-specific […]
Can Eli Lilly’s Two-Drug Obesity Treatment Justify Its $1 Trillion Valuation?
Eli Lilly stakes its trillion-dollar valuation on mid-stage data for a two-drug obesity combo, and the September 30 readout will reveal whether eloraTZP is a genuine franchise leap or an expensive gamble on incremental gains.
4 Biotech Stocks to Watch as Potential Takeover Targets
Biotech M&A surges in 2026, putting ABVX, IOVA, VKTX and BCRX on watchlists, as drugmakers seek late-stage and commercial assets.
LLY Stock Down Around 7% in a Month: Buy the Dip or Stay Cautious?
LLY's GLP-1 momentum, Foundayo launch and retatrutide pipeline support growth, but premium valuation and rising competition weigh on the stock.
Novo Falls 5% in a Week: How Should Investors Approach the Stock Now?
NVO's 5% drop in a week reflects intensifying GLP-1 competition and semaglutide risks, but its broad pipeline offers potential long-term growth.
Wall Street Sees a Huge Rebound for Viking Therapeutics. Here's Why Analysts Are So Optimistic.
The weight loss market is highly competitive, but Viking only needs to carve out a small niche in it with VK2735 in order to generate significant value for investors.
Viking Therapeutics: 3 Things To Watch In The Maintenance Data
Viking Therapeutics (VKTX) pushes GLP-1/GIP VK2735 into late-stage trials, but differentiation vs Zepbound is limitedâread risks, catalysts & data to watch.
Viking Therapeutics, Inc. (VKTX) Registers a Bigger Fall Than the Market: Important Facts to Note
The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $29.52, representing a -1.44% change from its previous close.
What's Going On With the Dip in Viking Therapeutics Stock?
Viking Therapeutics shares are dropping Tuesday amid a risk-off trade, though its longer-term uptrend and sector strength both remain intact.
Can Viking Therapeutics Beat Big Pharma With Monthly Weight-Loss Shots? Here’s The Risk CEO Says Could Derail It
CEO Brian Lian said monthly VK2735 must preserve weight loss without restarting nausea, vomiting and other gastrointestinal effects.
Viking Therapeutics Advances VK2735 Obesity Drug Into Phase 3 After 15% Weight Loss
Viking Therapeutics (NASDAQ:VKTX) said its obesity drug candidate VK2735 has advanced into Phase 3 development following Phase 2 results that showed approximately 15% weight loss from baseline after 13 weeks at the highest tested dose. Speaking at the Morgan Stanley Global Healthcare Conference, Pr
Viking Therapeutics, Inc. (VKTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Viking Therapeutics, Inc. (VKTX) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 3:20 PM EDTCompany ParticipantsBrian Lian -...
Will Morgan Stanley's NVO Downgrade Deepen Patent and Rival Woes?
Novo faces a tougher growth outlook as Morgan Stanley downgrades the stock to Underweight, citing muted growth, patent risks and rising pressure from Lilly.
Baron Global Opportunity Fund Q2 2026 Portfolio Activity
Baron Global Opportunity Fund (the Fund) gained 26.7% (Institutional Shares) during the second quarter, compared to the 14.9% gain for the MSCI ACWI Index (the Index). Read more here.
Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?
The average brokerage recommendation (ABR) for Viking Therapeutics (VKTX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Viking Therapeutics, Inc. (VKTX) Declines More Than Market: Some Information for Investors
Viking Therapeutics, Inc. (VKTX) closed the most recent trading day at $32.13, moving 1.74% from the previous trading session.
Axsome Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Axsome is already selling drugs with 65% revenue growth, while Viking bets on obesity treatments still in trials, a classic choice between proven sales and blockbuster potential.
Analysts Have a $92 Target on Viking Therapeutics. Here's What Has to Go Right to Get There.
This company aims to serve a market heading toward $100 billion.
Novo Nordisk's Semaglutide Meets Goal in Pediatric Obesity Study
NVO's semaglutide cuts BMI in children with obesity in phase III study, with 40.4% no longer classified as having obesity after 68 weeks.
Viking Therapeutics Trades Well Below Its Wall Street Targets. Here's the Skeptics' Case.
Investors always need to appreciate risk before buying into any clinical-stage biopharmaceutical company.
Is Viking Therapeutics (VKTX) Stock Fully Priced After A 411% Run?
Viking Therapeutics stock has delivered a very strong 5 year run, yet current valuation checks suggest the shares are priced at the richer end of the spectrum rather than as a clear bargain. Around 411.0% total return over 5 years highlights how much optimism has already been reflected in Viking Therapeutics shares. Progress of obesity candidate VK2735 and other metabolic programs, supported by a reported US$502 million cash position, can support high expectations, while any setback in...
Why Is Mirum Pharmaceuticals (MIRM) Up 6.9% Since Last Earnings Report?
Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-08-01 | Kelly-Gemmell Dorothy Elizabeth | +40,800 | - | - |
| 2026-08-01 | Kelly-Gemmell Dorothy Elizabeth | +6,333 | - | - |
| 2026-07-29 | Lian Brian | -148,517 | $33.3153 | $4,947,888 |
| 2026-07-29 | Mancini Marianna | -18,217 | $33.4652 | $609,636 |
| 2026-07-29 | ZANTE GREG | -21,217 | $33.4704 | $710,141 |
| 2026-07-28 | Lian Brian | +221,667 | - | - |
| 2026-07-28 | Mancini Marianna | +31,667 | - | - |
| 2026-07-28 | ZANTE GREG | +31,667 | - | - |
| 2026-06-01 | Chen Hubert C | +190,000 | - | - |
| 2026-03-10 | Aubuchon Neil William | +4,475 | $33.5 | $149,913 |
| 2026-01-12 | Aubuchon Neil William | +180,000 | - | - |
| 2026-01-05 | Mancini Marianna | -1,600 | $35.0731 | $56,117 |
| 2026-01-05 | Mancini Marianna | -10,500 | $34.2193 | $359,303 |
| 2026-01-05 | Mancini Marianna | -13,600 | $33.3732 | $453,876 |
| 2026-01-05 | Mancini Marianna | -31,961 | $32.2928 | $1,032,110 |
| 2026-01-05 | Lian Brian | -6,400 | $35.0661 | $224,423 |
| 2026-01-05 | Lian Brian | -41,276 | $34.2184 | $1,412,399 |
| 2026-01-05 | Lian Brian | -53,279 | $33.3765 | $1,778,267 |
| 2026-01-05 | Lian Brian | -132,454 | $32.2907 | $4,277,032 |
| 2026-01-05 | ZANTE GREG | -1,500 | $32.0887 | $48,133 |
| 2026-01-05 | ZANTE GREG | -10,300 | $34.2364 | $352,635 |
| 2026-01-05 | ZANTE GREG | -13,900 | $33.3828 | $464,021 |
| 2026-01-05 | ZANTE GREG | -31,961 | $32.295 | $1,032,180 |
| 2026-01-02 | Mancini Marianna | +91,000 | - | - |
| 2026-01-02 | Mancini Marianna | +32,049 | - | - |
| 2026-01-02 | Mancini Marianna | +41,000 | - | - |
| 2026-01-02 | Lian Brian | +176,300 | - | - |
| 2026-01-02 | Lian Brian | +224,080 | - | - |
| 2026-01-02 | Lian Brian | +78,400 | - | - |
| 2026-01-02 | Rouan Sarah Kathryn | +20,400 | - | - |
| 2026-01-02 | Rouan Sarah Kathryn | +3,150 | - | - |
| 2026-01-02 | MACARTNEY LAWSON | +20,400 | - | - |
| 2026-01-02 | MACARTNEY LAWSON | +3,150 | - | - |
| 2026-01-02 | Rowland Charles A Jr | +20,400 | - | - |
| 2026-01-02 | Rowland Charles A Jr | +3,150 | - | - |
| 2026-01-02 | ZANTE GREG | +91,000 | - | - |
| 2026-01-02 | ZANTE GREG | +32,049 | - | - |
| 2026-01-02 | ZANTE GREG | +41,000 | - | - |
| 2026-01-02 | SINGLETON J MATTHEW | +20,400 | - | - |
| 2026-01-02 | SINGLETON J MATTHEW | +3,150 | - | - |
| 2026-01-02 | FOEHR MATTHEW W | +20,400 | - | - |
| 2026-01-02 | FOEHR MATTHEW W | -16,000 | - | - |
| 2026-01-02 | FOEHR MATTHEW W | +3,150 | - | - |
| 2026-01-02 | FOEHR MATTHEW W | -16,000 | $35.1059 | $561,694 |
| 2026-01-02 | FOEHR MATTHEW W | +16,000 | $3.33 | $53,280 |
| 2025-10-28 | Mancini Marianna | -6,185 | $35.0027 | $216,492 |
| 2025-10-28 | Lian Brian | -38,989 | $35.0079 | $1,364,923 |
| 2025-10-28 | ZANTE GREG | -6,185 | $35.0009 | $216,481 |
| 2025-10-27 | Mancini Marianna | +11,117 | - | - |
| 2025-10-27 | Lian Brian | +70,084 | - | - |
| 2025-10-27 | Rowland Charles A Jr | -22,000 | - | - |
| 2025-10-27 | Rowland Charles A Jr | -22,000 | - | - |
| 2025-10-27 | Rowland Charles A Jr | -16,000 | - | - |
| 2025-10-27 | Rowland Charles A Jr | -60,000 | $35.5713 | $2,134,278 |
| 2025-10-27 | Rowland Charles A Jr | +22,000 | $4.88 | $107,360 |
| 2025-10-27 | Rowland Charles A Jr | +22,000 | $5.8 | $127,600 |
| 2025-10-27 | Rowland Charles A Jr | +16,000 | $4.48 | $71,680 |
| 2025-10-27 | ZANTE GREG | +11,117 | - | - |